{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:08:57Z","timestamp":1776179337007,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,26]]},"DOI":"10.7759\/cureus.49452","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T03:02:25Z","timestamp":1701054145000},"source":"Crossref","is-referenced-by-count":2,"title":["Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-cell Therapy: A Retrospective Study Analyzing Risks, Outcomes, and Healthcare Burden"],"prefix":"10.7759","author":[{"given":"Rushin","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mrunal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fehmida","family":"Laxmidhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khushboo","family":"Lakhatariya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darshil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zalak","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safia","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.27217.2","article-title":"Cancer T-cell therapy: building the foundation for a cure","volume":"9","author":"Kamb A","year":"2020","unstructured":"Kamb A, Go WY. Cancer T-cell therapy: building the foundation for a cure. F1000Res. 2020, 9:1295. 10.12688\/f1000research.27217.2","journal-title":"F1000Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","author":"Brudno JN","year":"2018","unstructured":"Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018, 15:31-46. 10.1038\/nrclinonc.2017.128","journal-title":"Nat Rev Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22042150","article-title":"A review of clinical outcomes of CAR T-cell therapies for B-acute lymphoblastic leukemia","volume":"22","author":"Martino M","year":"2021","unstructured":"Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione C. A review of clinical outcomes of CAR T-cell therapies for B-acute lymphoblastic leukemia. Int J Mol Sci. 2021, 22:2150. 10.3390\/ijms22042150","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112639","article-title":"CART-cell therapy: recent advances and new evidence in multiple myeloma","volume":"13","author":"Martino M","year":"2021","unstructured":"Martino M, Canale FA, Alati C, et al.. CART-cell therapy: recent advances and new evidence in multiple myeloma. Cancers (Basel). 2021, 13:2639. 10.3390\/cancers13112639","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.967754","article-title":"Chimeric antigen receptor T-cell therapy for T-ALL and AML","volume":"12","author":"Wei W","year":"2022","unstructured":"Wei W, Yang D, Chen X, Liang D, Zou L, Zhao X. Chimeric antigen receptor T-cell therapy for T-ALL and AML. Front Oncol. 2022, 12:967754. 10.3389\/fonc.2022.967754","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2844","article-title":"Optimizing CAR T cell therapy in lymphoma","volume":"39","author":"Qualls D","year":"2021","unstructured":"Qualls D, Salles G. Optimizing CAR T cell therapy in lymphoma. Hematol Oncol. 2021, 39:104-12. 10.1002\/hon.2844","journal-title":"Hematol Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen A","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, et al.. Cytokine release syndrome. J Immunother Cancer. 2018, 6:56. 10.1186\/s40425-018-0343-9","journal-title":"J Immunother Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-021-01948-2","article-title":"CAR T-cell therapy and critical care: a\u00a0survival guide for medical emergency teams","volume":"133","author":"Messmer AS","year":"2021","unstructured":"Messmer AS, Que YA, Schankin C, Banz Y, Bacher U, Novak U, Pabst T. CAR T-cell therapy and critical care: a\u00a0survival guide for medical emergency teams. Wien Klin Wochenschr. 2021, 133:1318-25. 10.1007\/s00508-021-01948-2","journal-title":"Wien Klin Wochenschr"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee DW","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, et al.. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014, 124:188-95. 10.1182\/blood-2014-05-552729","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno JN","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016, 127:3321-30. 10.1182\/blood-2016-04-703751","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1729735","article-title":"Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy","volume":"20","author":"Chou CK","year":"2020","unstructured":"Chou CK, Turtle CJ. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. Expert Opin Biol Ther. 2020, 20:653-64. 10.1080\/14712598.2020.1729735","journal-title":"Expert Opin Biol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine release syndrome: current perspectives","volume":"8","author":"Murthy H","year":"2019","unstructured":"Murthy H, Iqbal M, Chavez JC, Kharfan-Dabaja MA. Cytokine release syndrome: current perspectives. Immunotargets Ther. 2019, 8:43-52. 10.2147\/ITT.S202015","journal-title":"Immunotargets Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2017.09.002","article-title":"Cytokine release syndrome: who is at risk and how to treat","volume":"30","author":"Frey N","year":"2017","unstructured":"Frey N. Cytokine release syndrome: who is at risk and how to treat. Best Pract Res Clin Haematol. 2017, 30:336-40. 10.1016\/j.beha.2017.09.002","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref14","unstructured":"Agency for Healthcare Research and Quality. Overview of HCUP. (2022). Accessed. October 25, 2023: https:\/\/www.ahrq.gov\/data\/hcup\/index.html."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.17653","article-title":"Adherence to methodological standards in research using the National Inpatient Sample","volume":"318","author":"Khera R","year":"2017","unstructured":"Khera R, Angraal S, Couch T, et al.. Adherence to methodological standards in research using the National Inpatient Sample. JAMA. 2017, 318:2011-8. 10.1001\/jama.2017.17653","journal-title":"JAMA"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan V","year":"2004","unstructured":"Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004, 57:1288-94. 10.1016\/j.jclinepi.2004.03.012","journal-title":"J Clin Epidemiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1019115","article-title":"CAR-T cell therapy for hematological malignancies: limitations and optimization strategies","volume":"13","author":"Huang J","year":"2022","unstructured":"Huang J, Huang X, Huang J. CAR-T cell therapy for hematological malignancies: limitations and optimization strategies. Front Immunol. 2022, 13:1019115. 10.3389\/fimmu.2022.1019115","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau N","year":"2023","unstructured":"Gazeau N, Liang EC, Wu QV, et al.. Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2023, 29:430-7. 10.1016\/j.jtct.2023.04.001","journal-title":"Transplant Cell Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey N","year":"2019","unstructured":"Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019, 25:e123-7. 10.1016\/j.bbmt.2018.12.756","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001304","article-title":"Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Schuster SJ","year":"2020","unstructured":"Schuster SJ, Maziarz RT, Rusch ES, et al.. Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020, 4:1432-9. 10.1182\/bloodadvances.2019001304","journal-title":"Blood Adv"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","article-title":"Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL","volume":"36","author":"Abramson JS","year":"2018","unstructured":"Abramson JS, Gordon LI, Palomba ML, et al.. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL. J Clin Oncol. 2018, 36:7505. 10.1200\/JCO.2018.36.15_suppl.7505","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali SA","year":"2016","unstructured":"Ali SA, Shi V, Maric I, et al.. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016, 128:1688-700. 10.1182\/blood-2016-04-711903","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/nature09522","article-title":"Pericytes regulate the blood-brain barrier","volume":"468","author":"Armulik A","year":"2010","unstructured":"Armulik A, Genov\u00e9 G, M\u00e4e M, et al.. Pericytes regulate the blood-brain barrier. Nature. 2010, 468:557-61. 10.1038\/nature09522","journal-title":"Nature"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.03.021","article-title":"Health care resource utilization and total costs of care among patients with diffuse large B cell lymphoma treated with chimeric antigen receptor T cell therapy in the United States","volume":"28","author":"Keating SJ","year":"2022","unstructured":"Keating SJ, Gu T, Jun MP, McBride A. Health care resource utilization and total costs of care among patients with diffuse large B cell lymphoma treated with chimeric antigen receptor T cell therapy in the United States. Transplant Cell Ther. 2022, 28:404.e1-6. 10.1016\/j.jtct.2022.03.021","journal-title":"Transplant Cell Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950923","article-title":"The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions","volume":"13","author":"Li Y","year":"2022","unstructured":"Li Y, Ming Y, Fu R, et al.. The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. Front Pharmacol. 2022, 13:950923. 10.3389\/fphar.2022.950923","journal-title":"Front Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/208305-cytokine-release-syndrome-in-patients-treated-with-chimeric-antigen-receptor-t-cell-therapy-a-retrospective-study-analyzing-risks-outcomes-and-healthcare-burden","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:37Z","timestamp":1707509437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/208305-cytokine-release-syndrome-in-patients-treated-with-chimeric-antigen-receptor-t-cell-therapy-a-retrospective-study-analyzing-risks-outcomes-and-healthcare-burden"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,26]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.49452","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,26]]}}}